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Abstract 
Background: Chronic lymphocytic leukemia (CLL) remains incurable with standard therapy, and is characterized by 
excessive expansion of monoclonal abnormal mature B cells and more regulatory immune properties of T cell com-
partment. Thus, developing novel strategies to enhance immune function merits further investigation as a possible 
therapy for CLL.
Methods: We generated a fusion cytokine (fusokine) arising from the combination of human GM-CSF and IL-4 
(named GIFT4). Primary CLL cells were treated with GIFT4 or GM-CSG and IL-4 in vitro. GIFT4-triggered STAT5 signaling 
in CLL cells was examined by Western blot. The phenotype and secretome of GIFT4-treated CLL cells (GIFT4-CLL cells), 
and the immune stimulatory function of GIFT4-CLL cells on autologous T cells were analyzed by flow cytometry and 
luminex assay.
Results: GIFT4-CLL up-regulated the expression of co-stimulatory molecules CD40, CD80 and CD86 and adhesion 
molecule CD54. GIFT4-CLL cells secreted IL-1β, IL-6, ICAM-1 and substantial IL-2 relative to unstimulated CLL cells. 
GIFT4 treatment led to JAK1, JAK2 and JAK3-mediated hyper-phosphorylation of STAT5 in primary CLL cells, which is 
essential for GIFT4-triggered conversion of CLL cells. GIFT4-CLL cells directly propelled the expansion of autologous 
IFN-γ-producing CD314+ cytotoxic T cells in vitro, and that these could lyse autologous CLL cells. Furthermore, admin-
istration of GIFT4 protein promoted the expansion of human T cells in NOD-scid IL2Rγnull immune deficient mice 
adoptively pre-transferred with peripheral blood mononuclear cells from subjects with CLL.
Conclusion: GIFT4 has potent capability to converts primary CLL cells into APC-like immune helper cells that initiate 
a T cell driven anti-CLL immune response.
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Background
Chronic lymphocytic leukemia (CLL) is the most com-
mon leukemia in adults, and it is characterized by exces-
sive expansion of monoclonal abnormal mature B cells in 
peripheral blood, lymph node, spleen and bone marrow 
[1], and remains incurable with standard therapy [2, 3]. T 
cells in patients with CLL have more regulatory immune 
response and less immune synapse interaction with anti-
gen-presenting cells (APC) [4]. Thus, developing novel 
strategies to enhance immune function merits further 
investigation as a possible therapy for CLL. Emerging 
immunotherapies such as chimeric antigen receptor-
modified T cells (CART) [5] and anti-CD20 monoclo-
nal antibodies have shown improved outcomes for CLL 
management through direct attack on CLL B cells or 
activating complement membrane attack complex to lyse 
CLL B cells. However, B cell aplasia, decreased number 
of plasma cells, hypogammaglobulinemia and life-threat-
ening cytokine release syndrome remain a challenge for 
CART therapy [6, 7]. Augmented T cell activation and 
immunity by CD40 ligation [8] and immune checkpoint 
blockade [3], and developing CLL vaccines [9, 10] are 
under clinical investigation, which provide alternative 
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We have developed a novel fusion cytokine (fusokine) 
named GIFT4 that is derived from GM-CSF and IL-4 
[11], built upon the successful development of the GM-
CSF and interleukin transgene platforms [12, 13]. GIFT4 
protein has potent immune-stimulatory activity on B 
cells, and induces B cell proliferation through co-clus-
tering of GM-CSF receptor (GM-CSFR) and IL-4 recep-
tor (IL-4R) on the cell surface. GIFT4 treatment further 
programs naïve B cells into helper cells, which further 
license anti-tumor T cell response. Considering that CLL 
B cells express both IL-4R [14] and GM-CSFR [15], we 
tested whether GIFT4 could also have stimulatory effect 
on CLL cells, and reprogram the leukemic B cells into 
immune helper cells. Here we show that human GIFT4 
stimulation converts primary CLL B cells into APC-like 
cells with up-regulated expression of co-stimulatory mol-
ecules CD40, CD80 and CD86 on their surface. GIFT4-
converted CLL B cells (GIFT4-CLL cells) secreted IL-1β, 
IL-6, ICAM-1 and substantial IL-2, and primed autolo-




Peripheral blood was collected from 12 subjects with 
CLL (seven males and five females) listed in Table 1 fol-
lowing informed consent, as per a protocol approved by 
the Emory University Institutional Review Board.
GIFT4 protein
The GIFT4 chimeric transgene was cloned from human 
GM-CSF and IL-4 cDNA (Invivogen), and the fusion 
protein was produced in bio-engineered 293T cells as 
previously described [11]. GIFT4 protein was concen-
trated and quantified by ELISA kit with anti-human GM-
CSF antibodies (eBiosciences, San Diego, CA, USA).
Cell culture
PBMC were isolated from peripheral blood of subjects 
with CLL using lymphocyte isolation solution (Mediat-
ech). Primary CD5+CD19+ CLL cells were sorted from 
PBMC on a Becton–Dickinson FACS Aria Cell Sorter. 
T cells in PBMC were purified with T cell enrichment 
kits (StemCell). PBMC, primary CLL cells; T cells were 
cultured in complete RPMI-1640 medium (Corning, 
Manassas, VA, USA) for 5 days in presence of GIFT4 or 
recombinant GM-CSF and IL-4 control cytokines (2 ng/
ml) (PeproTech). Alternatively, the treated CLL cells were 
washed with fresh RPMI-1640 medium, and cultured for 
additional 48 h. Cell culture supernatants were then col-
lected and subjected to luminex assay with human 51plex 
cytokine polystyrene bead kit (Affymetrix, Santa Clara, 
CA, USA) in the Human Immunology Monitoring Center 
at Stanford University. For proliferation assay, PBMC 
or purified T cells from subjects with CLL were labeled 
with CFSE dye (Invitrogen, Eugene, OR, USA) following 
the manufacturer’s instruction, and cultured in complete 
RPMI 1640 medium for 5 days in presence of GIFT4 or 
GM-CSF and IL-4 (2  ng/ml). Autologous T cells were 
co-cultured with GIFT4-CLL cells or control cytokine-
stimulated CLL cells (1:1 ratio) for 4  days. T cells were 
then purified with human T cell positive selection kit 
(StemCell) and re-cultured (105/ml) in fresh RPMI-1640 
medium for additional 48 h. The T cell culture superna-
tants were subjected to luminex assay.
Flow cytometry
PBMC from subjects with CLL were stimulated with 
GIFT4 protein or GM-CSF and IL-4 (2 ng/ml) for 5 days. 
The cells were harvested and stained with APC-conju-
gated anti-human CD19 and PE-conjugated anti-human 
CD5 antibodies; or APC-conjugated anti-human CD3, 
then subjected to flow cytometry (FACS) on a BD FAC-
SCanto II flow cytometer. Phenotype of GIFT4-CLL 
cells was profiled by FACS with a panel of B cell anti-
bodies including anti-CD80 and CD86 (BD, San Diego, 
CA, USA). For analysis of cell–cell interaction between 
GIFT4-CLL cells and T cells, CFSE-labeled autologous T 
cells were co-cultured with GIFT4-CLL cells pre-treated 
with anti-human CD80 or CD86 neutralizing antibod-
ies or isotype control (1  μg/ml) (BioLegend) for 5  days. 
T cell division was determined by FACS. For intracellu-
lar staining of IFN-γ, Granzyme B, and perforin, T cells 
were fixed and permeabilized with BD Cytofix/Cytop-
erm™ solution, followed by staining with PE-conjugated 
Table 1 Characteristics of CLL subjects
CLL subject  
number
Gender Age CD5+CD19+ 
CLL cells
in PBMC (%)
1 M 78 93.2
2 F 74 87.6
3 M 64 93.8
4 M 57 81.6
5 M 72 86.1
6 M 38 84.2
7 F 56 95.6
8 F 75 82.6
9 F 52 81.0
10 F 76 87.4
11 M 54 94.7
12 M 62 86.0
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anti-human IFN-γ, granzyme B, perforin antibodies (BD). 
Alternatively, circulating human T cells in the peripheral 
blood of NSG immune deficient mice adoptively trans-
ferred with PBMC from CLL patients were profiled and 
counted by FACS, and analyzed with FlowJo 9.1 software.
Luminex assay
The culture supernatants of GIFT4-treated primary 
CLL cells or control CLL cells were harvested, and the 
secretome of GIFT4-CLL cells was analyzed by luminex 
assay with human 51plex cytokine polystyrene bead kit as 
described [11].
ELISA and western blot
IL-2 and IL-6 production by CLL cells was quantified 
with human IL-2 and IL-6 ELISA kit (eBiosciences, San 
Diego, CA, USA). CLL cells stimulated with human 
GIFT4 protein, GM-CSF and/or IL-4 (2 ng/ml) cytokines 
for 20 min in presence or absence of JAK inhibitors [11] 
were harvested, and lysed with protein lysate buffer sup-
plemented with protease and phosphatase inhibitors as 
described [11]. STAT5 phosphorylation in the treated 
CLL cells was examined by Western blot with anti-
pSTAT5 (Tyr694, D47E7) and anti-STAT5 antibodies 
(Cell Signaling, Boston, MA, USA).
Cell apoptosis assay
GIFT4-CLL primed cytotoxic T cells (105/ml) were co-
cultured with primary CLL cells (105/ml) in presence 
or absence of concanamycin (100  nM) (Sigma) for 24  h 
in a 96-well plate. The cells were collected and stained 
with APC-conjugated anti-human CD19 antibodies and 
Annexin V, then subjected to FACS analysis. Apoptotic 
cells were gated on Annexin V as previously described 
[16].
CLL xenograft in NSG mice
PBMC from subjects with CLL (108 cells/mouse) were 
adoptively transferred into NOD-scid IL2Rγnull NSG 
mice [17] by intravenous injection. The mice were then 
treated with human GIFT4 protein (20 ng/mouse/day) or 
control cytokines for 6 days. On day 7, 100 μl of periph-
eral blood collected from each mouse were stained 
with anti-human CD3 antibody for 30 min, followed by 
addition of red blood cell lysis buffer (for 10  min) and 
AccuCheck Counting Beads (Invitrogen) to quantify cir-
culating human T cell number as described [18, 19]. On 
day 30, human T cells in the peripheral blood of NSG 
mice were also analyzed by FACS with anti-human CD3 
antibody (BD) before the mice were sacrified. All mice 
used were female (6–8 weeks old) purchased from Jack-
son Laboratory (Bar Harbor, ME, USA). The mice were 
maintained in compliance with an IACUC protocol 
approved by Emory University.
Statistical analysis
Data were shown as mean ± SEM. P values were calcu-
lated using the one-way analysis of variance test. P value 
of less than 0.05 was considered significant (* P < 0.05; ** 
P < 0.01; *** P < 0.001).
Results
Human GIFT4 converts primary CLL B cells 
into antigen‑presenting cell phenotype
We previously demonstrated that human GIFT4 could 
expand and reprogram normal human B cells into anti-
tumor helper cells [11]. Thus we hypothesize that human 
GIFT4 protein (Fig. 1a) could have the capability to repro-
gram leukemic B cells into immune helper cells. To test 
the hypothesis, we isolated peripheral blood PBMC from 
the peripheral blood of subjects with CLL; the majority 
of peripheral blood mononuclear cells (PBMC) from the 
subjects we recruited are CD5+CD19+ leukemic B cells 
(Fig. 1b), ranged between 82.6 and 95.6 % with an average 
of 87.8  %. To check whether GIFT4 could promote the 
proliferation of CLL cells, the primary CLL B cells then 
were labeled with CFSE dye, then treated with human 
GIFT4 protein at a concentration of 2 ng/ml as previously 
described [11]. In contrast to GIFT4-induced expansion 
of normal human B cells [11], GIFT4 treatment did not 
trigger the proliferation of CLL B cells (Fig. 1c) although 
CLL B cells aggregated after GIFT4 stimulation (Fig. 1d), 
and did not activate peripheral T cells, NK cells or mono-
cytes from subjects with CLL (Data not show). Profiling 
the surface molecules by FACS showed that GIFT4-CLL 
cells are CD23+, CD40+, CD80+, CD86+, MHCI+, and 
MHCII+, with enhanced expression of CD54 and down-
regulation of CD27 and IL-4 receptor CD124 in compari-
son with control cytokine treatment (Fig. 1e). CLL cells 
treated with control cytokines or without treatment were 
absent of CD23, CD40, CD80 and CD86 (Fig. 1e).
Primary human CLL cells have been shown to produce 
or express a similar level of 174 cytokines and cytokine 
receptors as normal B cells did, except low levels of IL-6 
and eotaxin [20], and high levels of CXCR5 and CXCL13 
[21]. We tested whether GIFT4 treatment of CLL cells 
would alter their secretome. Purified primary CLL cells 
were treated with GIFT4 protein or GM-CSF and IL-4 
for 5  days. The cells were washed with fresh medium 
and cultured for additional 2 days. Luminex analyses on 
the culture supernatants showed that GIFT4-CLL cells 
produced significant amounts of immune-stimulatory 
cytokines and chemokines IL-6, IL-1β, VEGF, ICAM1 
(Fig.  2a), and substantial amounts of IL-2, IL-8 and 
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FGFB (Fig.  2b), in comparison with GM-CSF and IL-4 
treated, or untreated CLL cells. Primary untreated CLL 
cells secrete low levels of cytokine such as TNF-α, IL-1β, 
IL-6 and IL-8 as previous described [22]. GIFT4-CLL 
cells secreted little of IL-10, GM-CSF, IFN-γ, and CCL3 
(MIP1A) (Fig. 2a, b). There was no significant difference 
in the production of other cytokines and chemokines 
among GIFT4-CLL cells and CLL B cells treated with 
GM-CSF and IL-4 or PBS (Fig.  2c). However, there was 
a marked decrease of VCAM1 secretion by GIFT4-CLL 
cells compared with GM-CSF and IL-4 treated CLL cells 
(Fig. 2c).
STAT5/JAK signaling is essential for the conversion of CLL 
cells by GIFT4 treatment
Cytokine-triggered early STAT signaling plays an impor-
tant role in the regulation of gene expression and cell 
function [23]. In primary CLL cells, it has been reported 
that they deploy a constitutive increase of STAT1 and 
STAT3 phosphorylation [24, 25]. To explore the early 
STAT signaling events in CLL cells triggered by GIFT4 
protein, we stimulated primary CLL cells with the 
fusokine or control cytokines. Western blot analysis 
showed that GIFT4 stimulation exclusively induced the 
hyper phosphorylation of STAT5 in comparison with 
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Fig. 1 Phenotype of GIFT4-CLL cells. a Predicted 3D structure of GIFT4 protein. b A representative of CD19+CD5+ primary CLL cells in PBMC of sub-
jects. c Purified normal human B cells (White) or CLL cells were labeled with CFSE dye and treated with GIFT4 protein for 5 days; cell proliferation was 
analyzed by FACS. d CLL cells treated with GIFT4, GM-CSF and IL-4 or PBS were photographed under a microscope (×10). e CLL cells treated with 
GIFT4 (dark), GM-CSF and IL4 (gray), or PBS (white) were subjected to FACS analysis with a panel of antibodies against B cell markers or with antibody 
isotype control (Dash). Data are representative of one of four repeated experiments using samples from subjects No. 1, 2, 3 and 4
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GM-CSF and IL-4 treatment (Fig. 3a), but not of STAT1, 
STAT3 or STAT6 (data not shown). We further employed 
Janus protein tyrosine kinase 1 (JAK1), JAK2, and JAK3 
specific inhibitors to examine whether JAK signaling is 
involved in GIFT4-triggered STAT5 hyper phosphoryla-
tion in CLL cells. Addition of JAK2, JAK1/2, or JAK3 spe-
cific inhibitors into the cell culture system significantly 
suppressed hyper phosphorylation of STAT5 in GIFT4-
treated CLL cells (Fig.  3b). To determine the relevance 
of JAK signaling on the conversion of CLL cell pheno-
type by GIFT4 treatment, we utilized JAK inhibitors 
prior to GIFT4 stimulation. JAK1, JAK2 or JAK3 inhibi-
tors robustly suppressed the GIFT4-induced expression 
of co-stimulatory molecules CD80 (Fig.  3c) and CD86 
(Fig. 3d), but not CD40 (data not shown). To test whether 
GIFT4-induced STAT5/JAK signaling contributes to the 
cellular function of GIFT4-CLL cells on the production 
of immune stimulatory molecules, we used the same 
inhibitors to suppress JAK1, JAK2 and JAK3 signaling 
in the cell culture system respectively. We observed that 
inhibition of JAK signaling pathway significantly reduced 
the secretion of cytokine IL-2 (Fig. 3e) and IL-6 (Fig. 3f ) 
by GIFT4-CLL cells.
GIFT4‑primed CLL cells expand autologous T cells in vitro 
and in vivo
To examine whether the conversion of primary CLL cells 
by GIFT4 treatment could lead to the gain-of-function 
immune-stimulatory activities of GIFT4-CLL cells on 
autologous T cells, we stimulated the PBMC from CLL 
patients with GIFT4, GM-CSF and IL-4, or PBS for 
5  days. Profiling the cells by FACS showed that PBMC 
from subjects with CLL contained very low percentage 
of T cells (Fig. 4a). In comparison with CLL cells treated 
with control cytokine GM-CSF and IL-4 or without 
treatment, GIFT4-CLL cells induced robust prolifera-
tion of autologous T cells (Fig. 4b, c). The percentage of 
expanded autologous T cells in the co-cultured with CLL 
cells in presence of GIFT4 was 23.5  % on average, sig-




























































































































































































































Fig. 2 Secretome of GIFT4-CLL cells. Primary CLL cells were treated with GIFT4 (Dark), GM-CSF and IL-4 (Dark gray), IL-4 (Light gray) or PBS (White) 
for 5 days. The treated cells were harvested, washed, and re-culture for 24 h in fresh complete RPMI-1640 medium. The culture supernatants were 
collected and subjected to cytokine luminex assay with human 51plex cytokine polystyrene bead kit. a–c Cytokine and chemokine concentrations 
were calculated from three independent experiments using samples from subjects No. 2, 3 and 5
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the ones in control treatments (Fig. 4c); with more than 
eightfold increase of absolute T cell number compared 
with the initial T cell number in the culture (Fig.  4d). 
To exclude the possibility that GIFT4 could have direct 
effect on T cells, we co-cultured CSFE-labeled autolo-
gous T cells with GIFT4-CLL cells or GM-CSF and IL-4 
treated CLL cells, or with GIFT4 protein for 5  days. 
FACS analysis showed that GIFT4 stimulation alone 
without CLL cells could not induce T cell proliferation 
(Fig. 4e). To examine whether T cell expansion requires 
the cell–cell contact between GIFT4-CLL cells and 
autologous T cells, GIFT4-CLL cells were pre-incubated 
with anti-human CD80 or CD86 blocking antibodies. 
FACS analysis showed that blocking the co-stimulatory 
molecules inhibited T cell proliferation (Fig. 4f ). To test 
whether human GIFT4-CLL cells could promote the 
expansion of T cells from subjects with CLL in vivo, we 
adoptively transferred CLL-containing PBMC into NOD-
scid IL2Rγnull (NSG) immune deficient mice, and treated 
the mice with GIFT4, GM-CSF and IL-4 or PBS. FACS 
analysis on the peripheral blood of the mice with anti-
















































































































































































Fig. 3 GIFT4-induced STAT5/JAK signaling in CLL cells. a Primary CLL cells were stimulated with GIFT4, GM-CSF and IL-4 or PBS for 20 min. The 
cells were harvested and lysed. Ten microgram of proteins in the cell lysate was subjected to Western blot analysis with anti-pSTAT5 or anti-STAT5 
antibodies. b CLL cells were treated with GIFT4 protein in presence or absence of inhibitors for JAK2 (TG101348), JAK1/2 (INCB018424) or JAK3 
(CP690550). The cell lysate was subject to Western blot analysis with anti-pSTAT5 and anti- STAT5 antibodies. c, d CLL cells were stimulated with 
GIFT4 protein for 5 days, supplemented with JAK inhibitors. CD80 (c) and CD86 (d) expression on CLL cells treated with GIFT4 protein (Dark), or 
GIFT4 with JAK2 inhibitor (Dash), JAK1/2 inhibitor (White), JAK3 inhibitor (Gray) was analyzed by FACS. Mean fluorescent density was also quantified. 
e and f Cytokine IL-2 and IL-6 secretion by the treated CLL cells was quantified by ELISA with anti-IL-2 and anti-IL-6 antibodies, and calculated from 
three repeated experiments using samples from subjects No. 6, 8 and 9
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cells increased human T cell number in peripheral blood 
in comparison with GM-CSF and IL-4 or PBS control 
treatment (Fig. 5a). We also profiled human T cells in the 
treated NSG mice one month after treatment. In com-
parison with GM-CSF and IL-4 or PBS treatments, CLL 
cells treated with GIFT4 significantly enhanced the long-
term survival and expansion of T cells from CLL patients 
in the NSG mice (Fig.  5b, c). We observed there was a 
graft versus host disease in the GIFT4-treated NSG mice 
but not in PBS- or GM-CSF and IL-4 treated groups, due 
to the cytotoxicity of GIFT4-CLL cell-primed human T 
cells.
Human T cells primed by GIFT4‑CLL cells are cytotoxic 
and kill primary CLL cells
To characterize GIFT4-CLL cell-primed T cells, the 
supernatant of the T cells were subjected to luminex 
assay. In comparison with T cells primed by GM-
CSF and IL-4 or PBS treated CLL cells, GIFT4-CLL 
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Fig. 4 GIFT4 treatment induced the expansion of autologous T cells. PBMC were isolated from the peripheral blood of CLL patients, and stimulated 
with GIFT4, GM-CSF and IL-4 or PBS for 5 days. T cells in the PBMC before treatment (a), or after 5-day culture with GIFT4, GM-CSF and IL-4 or PBS (b) 
were profiled by FACS with anti-CD3 antibody; and T cell percentage and the absolute T cell number fold change were calculated from three inde-
pendent experiments using samples from subjects No. 7, 10, and 11 (c, d). e CSFE-labeled autologous T cells were co-cultured with GIFT4-CLL cells 
(Dark), GM-CSF and IL-4 treated CLL cells (Gray), untreated CLL cells (White), or with GIFT4 protein (Dash) for 4 days. f Alternatively, anti-human CD80 
(Gray), CD86 (White) neutralizing antibodies or isotype control (Black) were pre-incubated with GIFT4-CLL cells before co-cultured with CFSE-labeled 
autologous T cells. T cell division was analyzed by FACS (e, f)
Page 8 of 12Deng et al. J Transl Med  (2016) 14:106 
cytotoxic IFN-γ, MIP1A (CCL3), as well as FAS ligand, 
TRAIL, TNF-α, MIG (CXCL9), and IP-10 (Fig.  6a) 
relative to control. To further determine the cytotox-
icity of GIFT4-CLL cell-primed T cells, we performed 
intracellular staining of cytotoxic factors perforin and 
granzyme B, and surface staining of tumor-killing mol-
ecule CD314 (NKG2D) on those T cells. FACS analy-
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Fig. 5 GIFT4 treatment expanded human T cells in NSG mice. PBMC from the CLL patients were adoptively transferred into NSG immune deficient 
mice, and treated with GIFT4, GM-CSF and IL-4 or PBS for 6 days. a On Day 7, peripheral blood were collected from the treated mice, and circulating 
human T cells in the blood were analyzed by FACS with anti-human CD3 antibody. T cell number per 100 μl blood was calculated based on bead 
counting. b On day 30, circulating human T cells in PBMC of treated mice were also profiled by FACS with anti-human CD3 antibody, and percent-
age of human T cells was presented (c). Data were from three independent experiments using samples from subjects No. 1, 3 and 7
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are perforin+ and granzyme B+, and expressed CD314 
(Fig. 6b). To test whether GIFT4-CLL cell-primed cyto-
toxic T cells could have the capability to directly kill 
primary CLL cells, we co-cultured primary CLL cells 
with autologous GIFT4-CLL cell-primed T cells. T cells 
primed by GM-CSF and IL-4 or PBS treated CLL cells 
served as control T cells. After 24-h culture, the pri-
mary CLL cells were profiled by FACS with anti-human 
CD19 antibody and Annexin V. Apoptotic assay showed 
that GIFT4-CLL cell-primed T cells significantly 
induced apoptosis of the primary CLL cells in compari-
son with control T cells (Fig. 7a, b), with 30.8 % of aver-
age apoptotic death induced by GIFT4-CLL cell-primed 
T cells (Fig.  7d). However, GIFT4-CLL cell-primed T 
cells did not induce apoptotic death of normal human B 
cells (Fig. 7c). Killing of primary CLL cells by cytotoxic 
T cells was found through perforin-mediated pathway 
[26]. Indeed, addition of concanamycin, a specific per-
forin blocker [26], significantly suppressed the killing of 
autologous primary CLL cells by GIFT4-CLL primed T 
cells (Fig. 7a, b, d).
Discussion
In this study, we demonstrated that human GIFT4 can 
convert CLL B cells into immune-stimulatory helper 
cells, which function as APC and prime CLL-killing T 
cell response.
Primary CLL cells are monoclonal mature leukemic 
B cells that express CD5, CD19, CD20, IL-4 receptor 
(CD124), HLA-ABC and HLA-DR, but lack key T cell 
co-stimulatory molecules and adhesion molecules such 
as CD80, CD86, and CD54 [27]. It was reported that 
CD40 ligation of CLL B cells with CD40 ligand (CD154)-
transduced human embryonic fibroblast cells up-reg-
ulated CD54, CD80 and CD86, but not CD40 [28]. In 
another study, transduction of adenovirus encoding chi-
meric CD154 augmented CLL cells to behave as APC [8]. 
Untreated CLL cells express similar high levels of TLR9 
as normal B cells [29]. Activation of CLL cells with TLR9 
ligand type B CpG oligodeoxynucleotides (CpG-ODN) 
resulted in significant increase of CD40, CD54, CD86, 
HLA-ABC and HLA-DR expression, but not CD80 [30]. 
































Fig. 6 Secretome and cytotoxic factors of GIFT4-CLL cell primed T cells. a Autologous T cells primed by GIFT4-CLL cells (GIFT4/T cells) (Dark), GM-
CSF and IL-4 treated CLL cells (GM-CSF and IL-4/T cells) (Gray) or PBS-treated CLL cells (T cells) (White) were purified with T cell isolation kits and 
re-cultured in fresh RPMI medium. The T cell supernatants were subjected to luminex assay, and cytokine/chemokine concentration was calculated 
from three independent experiments. b Cytotoxic factors perforin, granzyme B and CD314 produced or expressed by GIFT4-CLL cell primed T cells 
(GIFT4/T cells) (Dark), or by GM-CSF and IL-4/T cells (Gray) or control T cells (White) were analyzed by FACS with intracellular staining of perforin, 
granzyme B or surface staining of CD314. Data were represented from one of three repeated experiments using samples from subjects No. 9, 10 
and 11
Page 10 of 12Deng et al. J Transl Med  (2016) 14:106 
IL-21 also enhanced the expression of CD54 and CD80, 
with slight increase of CD40 and CD86 on the cell surface, 
enabling CLL B cells functioned as APC-like cells [31].
Unlike primary CLL cells, CD40- or TLR9-ligated CLL 
cells, or CpG/IL-21 treated CLL cells, GIFT4-CLL cells 
robustly up-regulate the expression of co-stimulatory 
molecules CD40, CD80 and CD86 and adhesion molecule 
CD54, which are likely essential surface factors for GIFT4-
CLL cells functioning as APC to interact with T cells and 
prime T cell responses. Moreover GIFT4-CLL cells pro-
duce substantial amounts of IL-2, IL-8, FGFB, ICAM1, 
and IL-6, without significant production of GM-CSF, 
IFN-γ and CCL3. GIFT4-CLL cells are distinguished from 
our prior GIFT4-B cells that secrete GM-CSF and CCL3 
[11] and different from CD40/OX40-ligated CLL cells that 
produce IFN-γ [28], or CpG/IL-21 treated CLL cells that 
do not produce IL-2, ICAM-1, IL-6 and FGFB but secrete 
granzyme B [31]. It has been reported that primary CLL 
cells produce CCL3 chemokine [20], however, we could 
not detect the chemokine in both untreated or GIFT4-
treated CLL cells. Interesting, B cell receptor engagement 
with anti-IgM significantly enhanced chemokine CCL3 as 
well as CCL4 production by CLL cells [32]. Collectively, 
our data showed that GIFT4-converted CLL cells pos-
sess a unique phenotype and secretome, which facilitates 
GIFT4-CLL cells to function as potent APC.
JAK/STAT signaling plays an important role in the sur-
vival and surface molecule expression of CLL B cells [14, 
15, 33, 34]. CLL cells express both IL-4R and GM-CSFR. 
The binding of IL-4R by IL-4 activates JAK signaling [34], 
and leads to the phosphorylation of STAT1, STAT5, and 
STAT6 that enhances the survival of CLL cells [14, 34]. 
Unlike normal human B cells, CLL cells only express the 
GM-CSFR α, but not β subunit [15, 34, 35]. GM-CSFR α 
was showed to link with the activation of STAT3 and to 
promote the survival of CLL cells [15]. GIFT4 has been 
previously shown to induce hyper phosphorylation of 
pan-STAT including STAT1, STAT3, STAT5 and STAT6 
in normal B cells by clustering GM-CSFR and IL-4R on 
the cell surface and engagement of JAK1, JAK2 and JAK3 
signaling [11]. Indeed, we observed that GIFT4 stimula-
tion also induced hyper phosphorylation of STAT5 in CLL 
cells, which is involved in upstream collaborative signal-
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Fig. 7 Killing of primary CLL cells by GIFT4-CLL cell primed T cells. a, b Primary CLL cells were co-cultured with normal T cells (PBS T cells), or with T 
cells primed by GM-CSF and IL-4 treated CLL cells (GMCS + IL4 T cells), or with GIFT4-CLL cell-primed autologous cytotoxic T cells (GIFT4 T cells) (1:1 
ratio) in absence or presence of perforin inhibitor concanamycin for 24 h. The cells were then harvested and stained with anti-human CD19 anti-
body and Annexin V, and subjected to apoptotic analysis by FACS. b Combined histogram of Annexin V positive primary CLL cells. c Alternatively, 
normal B cells isolated from healthy subjects were co-cultured with GIFT4-CLL cell-primed T cells for 24 h before subjected to FACS analysis with 
Annexin V. d Percentage of apoptotic death of primary CLL cells in the treated groups was calculated from three independent experiments using 
samples from subjects No. 4, 8 and 12
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JAK/STAT5 signaling further contributes to both the 
expression of co-stimulatory molecules CD80 and CD86, 
and the production of T cell-promoting cytokines IL-2 
and IL-6 by GIFT4-CLL cells. However, we did not detect 
hyper phosphorylation of STAT1, STAT3 and STAT6 in 
CLL cells by GIFT4 exposure. Whether the lack of GM-
CSFR β is linked to the absence of hyper phosphorylation 
of STAT1, STAT3 and STAT6 in CLL cells by GIFT4 stim-
ulation remains to be determined.
Modified B cells have been utilized for cancer immu-
notherapy [36, 37]. Activated B cells acting as APC can 
elicit anti-tumor T cell response [11, 38, 39] or possess 
tumor-killing ability independently or through anti-
tumor antibody production [40, 41]. Previous studies 
have also shown that in vitro modified CLL cells hyper-
expressing adhesion molecules B7-1, ICAM-1 and LFA-3 
[42], CD40 ligand [43] or both CD40 ligand and IL-2 [44] 
may enhance effective T cell responses against CLL cells. 
Vaccination of whole CLL cells admixed with irradiated 
GM-CSF-secreting K562 bystander cells also promoted 
the expansion of IFN-γ+ leukemic-reactive T cells against 
CLL in patients after hematopoietic stem cell transplan-
tation [9]. GIFT4-CLL cells appear to have profound 
antigen presentation properties that may improve upon 
these approaches. GIFT4-converted CLL cells not only 
express immune co-stimulatory molecules CD40, CD80, 
CD86 and adhesion molecule ICAM-1 but also secrete 
immune-stimulatory cytokines IL-2 and IL-6, and have 
the potent ability to promote the expansion of autologous 
T cells. Those T cells produce cytotoxic factors such as 
IFN-γ, perforin, granzyme B, TRAIL, FAS ligand, CD314, 
and can directly kill primary CLL cells through perforin-
mediated pathway. To our knowledge, this is the first 
report that primary CLL cells from subjects with CLL 
can be reprogrammed to anti-CLL immune helper cells.
Conclusions
GIFT4 fusokine has potent capability to reprogram CLL 
cells into APC-like effectors, expressing co-stimulatory 
molecules CD40, CD80, CD86, and adhesion molecules 
CD54. GIFT4-CLL cells secreted immune stimulatory 
cytokines IL-1β, IL-6, ICAM-1 and substantial IL-2, and 
prime autologous T cells into IFN-γ-producing CD314+ 
CLL-killer cells. The exclusive characteristics and the 
unique functions of GIFT4 and GIFT4-CLL cells sup-
port the notion that GIFT4 fusokine and GIFT4-CLL 
cells could be utilized as novel therapeutics for CLL 
immunotherapy.
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